<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/84858175462</prism:url><dc:identifier>SCOPUS_ID:84858175462</dc:identifier><eid>2-s2.0-84858175462</eid><pii>HP33N5437J635431</pii><prism:doi>10.2478/v10019-012-0007-1</prism:doi><dc:title>Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>22</citedby-count><prism:publicationName>Radiology and Oncology</prism:publicationName><dc:publisher>
Association of Radiology and Oncology
</dc:publisher><source-id>17866</source-id><prism:issn>15813207 13182099</prism:issn><prism:volume>46</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:startingPage>54</prism:startingPage><prism:endingPage>59</prism:endingPage><prism:pageRange>54-59</prism:pageRange><prism:coverDate>2012-03-01</prism:coverDate><openaccess>1</openaccess><openaccessFlag>true</openaccessFlag><dc:creator><author seq="1" auid="55861939900"><ce:initials>M.</ce:initials><ce:indexed-name>Lekic M.</ce:indexed-name><ce:surname>Lekic</ce:surname><ce:given-name>Mirko</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Lekic M.</ce:indexed-name><ce:surname>Lekic</ce:surname><ce:given-name>Mirko</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55861939900</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng">
<ce:para>Background. Small cell lung cancer (SCLC) represents approximately 13 to 18% of all lung cancers. It is the most aggressive among lung cancers, mostly presented at an advanced stage, with median survival rates of 10 to12 months in patients treated with standard chemotherapy and radiotherapy. In approximately 15-20% of patients brain metastases are present already at the time of primary diagnosis; however, it is unclear how much it influences the outcome of disease according the other metastatic localisation. The objective of this analysis was to evaluate the median survival of SCLC patients treated by specific therapy (chemotherapy and/or radiotherapy) with regard to the presence or absence of brain metastases at the time of diagnosis. Patients and methods. All SCLC patients have been treated in a routine clinical practice and followed up at the University Clinic Golnik in Slovenia. In the retrospective study the medical files from 2002 to 2007 were review. All patients with cytological or histological confirmed disease and eligible for specific oncological treatment were included in the study. They have been treated according to the guidelines valid at the time. Chemotherapy and regular followed-up were carried out at the University Clinic Golnik and radiotherapy at the Institute of Oncology Ljubljana. Results. We found 251 patients eligible for the study. The median age of them was 65 years, majority were male (67%), smokers or ex-smokers (98%), with performance status 0 to 1 (83%). At the time of diagnosis no metastases were found in 64 patients (25.5%) and metastases outside the brain were presented in 153 (61.0%). Brain metastases, confirmed by a CT scan, were present in 34 patients (13.5%), most of them had also metastases at other localisations. All patients received chemotherapy and all patients with confirmed brain metastases received whole brain irradiation (WBRT). The radiotherapy with radical dose at primary tumour was delivered to 27 patients with limited disease and they got 4-6 cycles of chemotherapy. Median overall survival (OS) of 34 patients with brain metastases was 9 months (95% CI 6-12) while OS of 153 patients with metastases in other locations was 11 months (95% CI 10-12); the difference did not reach the level of significance (p = 0.62). As expected, the OS of patients without metastases at the time of primary diagnosis turned out to be significantly better compared to the survival of patients with either brain or other location metastases at the primary diagnosis (15 months vs 9 and 11 months, respectively, p &lt; 0.001). Conclusions. In our investigated population, the prognosis of patients with extensive SCLS with brain metastases at the primary diagnosis treated with chemotherapy and WBRT was not significantly worse compared to the prognosis of patients with extensive SCLC and metastases outside the brain. In extensive SCLC brain metastases were not a negative prognostic factor per se if the patients were able to be treated appropriately. However, the survival rates of extensive SCLC with or without brain metastases remained poor and novel treatment approaches are needed. The major strength of this study is that it has been done on a population of patients treated in a routine clinical setting.</ce:para>
</abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/84858175462" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=84858175462&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=84858175462&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"><affilname>Bolnišnica Golnik</affilname><affiliation-city>Golnik</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"><affilname>University of Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"><affilname>Onkološki inštitut Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><authors><author seq="1" auid="55861939900"><ce:initials>M.</ce:initials><ce:indexed-name>Lekic M.</ce:indexed-name><ce:surname>Lekic</ce:surname><ce:given-name>Mirko</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Lekic M.</ce:indexed-name><ce:surname>Lekic</ce:surname><ce:given-name>Mirko</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55861939900</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="2" auid="7005444734"><ce:initials>V.</ce:initials><ce:indexed-name>Kovac V.</ce:indexed-name><ce:surname>Kovac</ce:surname><ce:given-name>Viljem</ce:given-name><preferred-name><ce:initials>V.</ce:initials><ce:indexed-name>Kovac V.</ce:indexed-name><ce:surname>Kovac</ce:surname><ce:given-name>Viljem</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7005444734</author-url><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"/></author><author seq="3" auid="12753947800"><ce:initials>N.</ce:initials><ce:indexed-name>Triller N.</ce:indexed-name><ce:surname>Triller</ce:surname><ce:given-name>Nadja</ce:given-name><preferred-name><ce:initials>N.</ce:initials><ce:indexed-name>Triller N.</ce:indexed-name><ce:surname>Triller</ce:surname><ce:given-name>Nadja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/12753947800</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="4" auid="23976089500"><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><ce:given-name>Lea</ce:given-name><preferred-name><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><ce:given-name>Lea</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/23976089500</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="5" auid="55883901600"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55883901600</author-url><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"/></author><author seq="6" auid="7004393140"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7004393140</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>brain metastases</author-keyword><author-keyword>prophylactic cranial irradiation</author-keyword><author-keyword>small-cell lung cancer</author-keyword></authkeywords><idxterms/><subject-areas><subject-area code="2730" abbrev="MEDI">Oncology</subject-area><subject-area code="2741" abbrev="MEDI">Radiology, Nuclear Medicine and Imaging</subject-area></subject-areas><item xmlns=""><xocs:meta><xocs:funding-list has-funding-info="1" pui-match="primary"><xocs:funding-addon-generated-timestamp>2017-12-10T13:24:48.258Z</xocs:funding-addon-generated-timestamp></xocs:funding-list></xocs:meta><ait:process-info><ait:date-delivered day="17" month="06" timestamp="2015-06-17T09:06:13.000013+01:00" year="2015"/><ait:date-sort day="01" month="03" year="2012"/><ait:status stage="S300" state="update" type="core"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2015 Elsevier B.V., All rights reserved.</copyright><itemidlist>
<ce:pii>HP33N5437J635431</ce:pii>
<ce:doi>10.2478/v10019-012-0007-1</ce:doi>
<itemid idtype="PUI">364427721</itemid>
<itemid idtype="CAR-ID">298152830</itemid>
<itemid idtype="EMBASE">2012150057</itemid>
<itemid idtype="SCP">84858175462</itemid>
<itemid idtype="SGR">84858175462</itemid>
</itemidlist><history>
<date-created day="19" month="03" year="2012"/>
</history><dbcollection>EMBASE</dbcollection><dbcollection>Scopusbase</dbcollection></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords>
<author-keyword>brain metastases</author-keyword>
<author-keyword>prophylactic cranial irradiation</author-keyword>
<author-keyword>small-cell lung cancer</author-keyword>
</author-keywords></citation-info><citation-title><titletext original="y" xml:lang="eng" language="English">Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting</titletext></citation-title><author-group><author auid="55861939900" seq="1" type="auth"><ce:initials>M.</ce:initials><ce:indexed-name>Lekic M.</ce:indexed-name><ce:surname>Lekic</ce:surname><ce:given-name>Mirko</ce:given-name><preferred-name>
<ce:initials>M.</ce:initials>
<ce:indexed-name>Lekic M.</ce:indexed-name>
<ce:surname>Lekic</ce:surname>
<ce:given-name>Mirko</ce:given-name>
</preferred-name></author><author auid="12753947800" seq="3" type="auth"><ce:initials>N.</ce:initials><ce:indexed-name>Triller N.</ce:indexed-name><ce:surname>Triller</ce:surname><ce:given-name>Nadja</ce:given-name><preferred-name>
<ce:initials>N.</ce:initials>
<ce:indexed-name>Triller N.</ce:indexed-name>
<ce:surname>Triller</ce:surname>
<ce:given-name>Nadja</ce:given-name>
</preferred-name></author><author auid="23976089500" seq="4" type="auth"><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><ce:given-name>Lea</ce:given-name><preferred-name>
<ce:initials>L.</ce:initials>
<ce:indexed-name>Knez L.</ce:indexed-name>
<ce:surname>Knez</ce:surname>
<ce:given-name>Lea</ce:given-name>
</preferred-name></author><author auid="7004393140" seq="6" type="auth"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name>
<ce:initials>T.</ce:initials>
<ce:indexed-name>Cufer T.</ce:indexed-name>
<ce:surname>Cufer</ce:surname>
<ce:given-name>Tanja</ce:given-name>
</preferred-name></author><affiliation afid="60078312" country="svn"><organization>University Clinic for Respiratory and Allergic Diseases Golnik</organization><country>Slovenia</country></affiliation></author-group><author-group><author auid="7005444734" seq="2" type="auth"><ce:initials>V.</ce:initials><ce:indexed-name>Kovac V.</ce:indexed-name><ce:surname>Kovac</ce:surname><ce:given-name>Viljem</ce:given-name><preferred-name>
<ce:initials>V.</ce:initials>
<ce:indexed-name>Kovac V.</ce:indexed-name>
<ce:surname>Kovac</ce:surname>
<ce:given-name>Viljem</ce:given-name>
</preferred-name></author><affiliation afid="60000966" country="svn"><organization>Institute of Oncology Ljubljana</organization><city-group>Ljubljana</city-group><country>Slovenia</country></affiliation></author-group><author-group><author auid="55883901600" seq="5" type="auth"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name>
<ce:initials>A.</ce:initials>
<ce:indexed-name>Sadikov A.</ce:indexed-name>
<ce:surname>Sadikov</ce:surname>
<ce:given-name>Aleksander</ce:given-name>
</preferred-name></author><affiliation afid="60031106" country="svn"><organization>University of Ljubljana, Faculty of Computer and Information Science</organization><country>Slovenia</country></affiliation></author-group><correspondence><person>
<ce:initials>T.</ce:initials>
<ce:indexed-name>Cufer T.</ce:indexed-name>
<ce:degrees>Dr. Prof.</ce:degrees>
<ce:surname>Cufer</ce:surname>
</person><affiliation country="svn"><organization>University Clinic for Respiratory and Allergic Diseases Golnik</organization><country>Slovenia</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng">
<ce:para>Background. Small cell lung cancer (SCLC) represents approximately 13 to 18% of all lung cancers. It is the most aggressive among lung cancers, mostly presented at an advanced stage, with median survival rates of 10 to12 months in patients treated with standard chemotherapy and radiotherapy. In approximately 15-20% of patients brain metastases are present already at the time of primary diagnosis; however, it is unclear how much it influences the outcome of disease according the other metastatic localisation. The objective of this analysis was to evaluate the median survival of SCLC patients treated by specific therapy (chemotherapy and/or radiotherapy) with regard to the presence or absence of brain metastases at the time of diagnosis. Patients and methods. All SCLC patients have been treated in a routine clinical practice and followed up at the University Clinic Golnik in Slovenia. In the retrospective study the medical files from 2002 to 2007 were review. All patients with cytological or histological confirmed disease and eligible for specific oncological treatment were included in the study. They have been treated according to the guidelines valid at the time. Chemotherapy and regular followed-up were carried out at the University Clinic Golnik and radiotherapy at the Institute of Oncology Ljubljana. Results. We found 251 patients eligible for the study. The median age of them was 65 years, majority were male (67%), smokers or ex-smokers (98%), with performance status 0 to 1 (83%). At the time of diagnosis no metastases were found in 64 patients (25.5%) and metastases outside the brain were presented in 153 (61.0%). Brain metastases, confirmed by a CT scan, were present in 34 patients (13.5%), most of them had also metastases at other localisations. All patients received chemotherapy and all patients with confirmed brain metastases received whole brain irradiation (WBRT). The radiotherapy with radical dose at primary tumour was delivered to 27 patients with limited disease and they got 4-6 cycles of chemotherapy. Median overall survival (OS) of 34 patients with brain metastases was 9 months (95% CI 6-12) while OS of 153 patients with metastases in other locations was 11 months (95% CI 10-12); the difference did not reach the level of significance (p = 0.62). As expected, the OS of patients without metastases at the time of primary diagnosis turned out to be significantly better compared to the survival of patients with either brain or other location metastases at the primary diagnosis (15 months vs 9 and 11 months, respectively, p &lt; 0.001). Conclusions. In our investigated population, the prognosis of patients with extensive SCLS with brain metastases at the primary diagnosis treated with chemotherapy and WBRT was not significantly worse compared to the prognosis of patients with extensive SCLC and metastases outside the brain. In extensive SCLC brain metastases were not a negative prognostic factor per se if the patients were able to be treated appropriately. However, the survival rates of extensive SCLC with or without brain metastases remained poor and novel treatment approaches are needed. The major strength of this study is that it has been done on a population of patients treated in a routine clinical setting.</ce:para>
</abstract></abstracts><source country="svn" srcid="17866" type="j"><sourcetitle>Radiology and Oncology</sourcetitle><sourcetitle-abbrev>Radiol. Oncol.</sourcetitle-abbrev><translated-sourcetitle xml:lang="eng">Radiology and Oncology</translated-sourcetitle><issn type="electronic">15813207</issn><issn type="print">13182099</issn><codencode>RONCE</codencode><volisspag>
<voliss issue="1" volume="46"/>
<pagerange first="54" last="59"/>
</volisspag><publicationyear first="2012"/><publicationdate>
<year>2012</year>
<month>03</month>
<day>01</day>
<date-text xfab-added="true">1 March 2012</date-text></publicationdate><website>
<ce:e-address type="email">http://www.degruyter.com/view/j/raon</ce:e-address>
</website><publisher>
<publishername>Association of Radiology and Oncology</publishername>
</publisher></source><enhancement><classificationgroup>
<classifications type="ASJC">
<classification>2730</classification>
<classification>2741</classification>
</classifications><classifications type="SUBJABBR"><classification>MEDI</classification></classifications>
<classifications type="EMCLASS">
<classification> <classification-code>14</classification-code> <classification-description>Radiology</classification-description> </classification>
<classification> <classification-code>16</classification-code> <classification-description>Cancer</classification-description> </classification>
<classification> <classification-code>37</classification-code> <classification-description>Drug Literature Index</classification-description> </classification>
<classification> <classification-code>8</classification-code> <classification-description>Neurology and Neurosurgery</classification-description> </classification>
</classifications>
</classificationgroup><chemicalgroup>
<chemicals source="esbd">
<chemical>
<chemical-name>cisplatin</chemical-name>
<cas-registry-number>15663-27-1</cas-registry-number>
<cas-registry-number>26035-31-4</cas-registry-number>
<cas-registry-number>96081-74-2</cas-registry-number>
</chemical>
<chemical>
<chemical-name>cyclophosphamide</chemical-name>
<cas-registry-number>50-18-0</cas-registry-number>
</chemical>
<chemical>
<chemical-name>doxorubicin</chemical-name>
<cas-registry-number>23214-92-8</cas-registry-number>
<cas-registry-number>25316-40-9</cas-registry-number>
</chemical>
<chemical>
<chemical-name>etoposide</chemical-name>
<cas-registry-number>33419-42-0</cas-registry-number>
</chemical>
<chemical>
<chemical-name>vincristine</chemical-name>
<cas-registry-number>57-22-7</cas-registry-number>
</chemical>
</chemicals>
</chemicalgroup></enhancement></head><tail><bibliography refcount="30">
<reference id="1">
<ref-info>
<ref-title>
<ref-titletext>Changing trends in the distribution of the histologic types of lung cancer: A review of 4,439 cases</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">33847606966</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Wahbah M.</ce:indexed-name>
<ce:surname>Wahbah</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:indexed-name>Boroumand N.</ce:indexed-name>
<ce:surname>Boroumand</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Castro C.</ce:indexed-name>
<ce:surname>Castro</ce:surname>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:indexed-name>El-Zeky F.</ce:indexed-name>
<ce:surname>El-Zeky</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Eltorky M.</ce:indexed-name>
<ce:surname>Eltorky</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Annals of Diagnostic Pathology</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-volisspag>
<voliss issue="2" volume="11"/>
<pagerange first="89" last="96"/>
</ref-volisspag>
<ref-text>DOI 10.1016/j.anndiagpath.2006.04.006, PII S1092913406000530</ref-text>
</ref-info>
<ref-fulltext>Wahbah M, Boroumand N, Castro C, El-Zeky F, Eltorky M. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol 2007; 11: 89-96. (Pubitemid 46350914)</ref-fulltext>
</reference>
<reference id="2">
<ref-info>
<ref-title>
<ref-titletext>Lung</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">84864367529</itemid>
</refd-itemidlist>
<ref-sourcetitle>TNM Classification of Malignant Tumours</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<pagerange first="138" last="146"/>
</ref-volisspag>
<ref-text>UICC International Union Against Cancer. Sobin LH, Gospodarowicz MK, Wittekind Ch, editors. 7th edition. Chichester: Wiley-Blackwell</ref-text>
</ref-info>
<ref-fulltext>UICC International Union Against Cancer. Lung. In: Sobin LH, Gospodarowicz MK, Wittekind Ch, editors. TNM classification of malignant tumours. 7th edition. Chichester: Wiley-Blackwell, 2009. p. 138-46.</ref-fulltext>
</reference>
<reference id="3">
<ref-info>
<ref-title>
<ref-titletext>The progress in routine management of lung cancer patients. A comparative analysis of an institution in 1996 and 2006</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">62949138043</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Debevec L.</ce:indexed-name>
<ce:surname>Debevec</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Jeric T.</ce:indexed-name>
<ce:surname>Jerič</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:indexed-name>Kovac V.</ce:indexed-name>
<ce:surname>Kovač</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Sok M.</ce:indexed-name>
<ce:surname>Sok</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Bitenc M.</ce:indexed-name>
<ce:surname>Bitenc</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Radiol Oncol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss volume="43"/>
<pagerange first="47" last="53"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Debevec L, Jerič T, Kovač V, Sok M, Bitenc M. The progress in routine management of lung cancer patients. A comparative analysis of an institution in 1996 and 2006. Radiol Oncol 2009; 43: 47-53.</ref-fulltext>
</reference>
<reference id="4">
<ref-info>
<ref-title>
<ref-titletext>The IASLC Lung Cancer Staging Project: Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">69549097677</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Vallieres E.</ce:indexed-name>
<ce:surname>Vallières</ce:surname>
</author>
<author seq="2">
<ce:initials>F.A.</ce:initials>
<ce:indexed-name>Shepherd F.A.</ce:indexed-name>
<ce:surname>Shepherd</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Crowley J.</ce:indexed-name>
<ce:surname>Crowley</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Van Houtte P.</ce:indexed-name>
<ce:surname>Van Houtte</ce:surname>
</author>
<author seq="5">
<ce:initials>P.E.</ce:initials>
<ce:indexed-name>Postmus P.E.</ce:indexed-name>
<ce:surname>Postmus</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:indexed-name>Carney D.</ce:indexed-name>
<ce:surname>Carney</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J Thorac Oncol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss volume="4"/>
<pagerange first="1049" last="1059"/>
</ref-volisspag>
<ref-text>International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions</ref-text>
</ref-info>
<ref-fulltext>Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, et al International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4: 1049-59.</ref-fulltext>
</reference>
<reference id="5">
<ref-info>
<ref-title>
<ref-titletext>Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer - What limits limited disease?</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">0036753654</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Micke P.</ce:indexed-name>
<ce:surname>Micke</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Faldum A.</ce:indexed-name>
<ce:surname>Faldum</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Metz T.</ce:indexed-name>
<ce:surname>Metz</ce:surname>
</author>
<author seq="4">
<ce:initials>K.-M.</ce:initials>
<ce:indexed-name>Beeh K.-M.</ce:indexed-name>
<ce:surname>Beeh</ce:surname>
</author>
<author seq="5">
<ce:initials>F.</ce:initials>
<ce:indexed-name>Bittinger F.</ce:indexed-name>
<ce:surname>Bittinger</ce:surname>
</author>
<author seq="6">
<ce:initials>J.-G.</ce:initials>
<ce:indexed-name>Hengstler J.-G.</ce:indexed-name>
<ce:surname>Hengstler</ce:surname>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Buhl R.</ce:indexed-name>
<ce:surname>Buhl</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<ref-volisspag>
<voliss issue="3" volume="37"/>
<pagerange first="271" last="276"/>
</ref-volisspag>
<ref-text>DOI 10.1016/S0169-5002(02)00072-7, PII S0169500202000727</ref-text>
</ref-info>
<ref-fulltext>Micke P, Faldum A, Metz T, Beeha K, Bittingerc F, Hengstlerd J, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer - what limits limited disease? Lung Cancer 2002; 37: 271-6. (Pubitemid 35286725)</ref-fulltext>
</reference>
<reference id="6">
<ref-info>
<ref-title>
<ref-titletext>A review of first-line treatment for small-cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">33947582831</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:indexed-name>Murray N.</ce:indexed-name>
<ce:surname>Murray</ce:surname>
</author>
<author seq="2">
<ce:initials>A.T.</ce:initials>
<ce:indexed-name>Turrisi III A.T.</ce:indexed-name>
<ce:surname>Turrisi III</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Journal of Thoracic Oncology</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-volisspag>
<voliss issue="3" volume="1"/>
<pagerange first="270" last="278"/>
</ref-volisspag>
<ref-text>PII 0124389420060300000014</ref-text>
</ref-info>
<ref-fulltext>Murray N, Turrisi AT 3rd. A review of first-line treatment for small cell lung cancer. J Thorac Oncol 2006; 1: 270-8. (Pubitemid 47181446)</ref-fulltext>
</reference>
<reference id="7">
<ref-info>
<ref-title>
<ref-titletext>Current and evolving treatment options for limited stage small cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">33646672614</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>C.B.</ce:initials>
<ce:indexed-name>Lee C.B.</ce:indexed-name>
<ce:surname>Lee</ce:surname>
</author>
<author seq="2">
<ce:initials>D.E.</ce:initials>
<ce:indexed-name>Morris D.E.</ce:indexed-name>
<ce:surname>Morris</ce:surname>
</author>
<author seq="3">
<ce:initials>D.B.</ce:initials>
<ce:indexed-name>Fried D.B.</ce:indexed-name>
<ce:surname>Fried</ce:surname>
</author>
<author seq="4">
<ce:initials>M.A.</ce:initials>
<ce:indexed-name>Socinski M.A.</ce:indexed-name>
<ce:surname>Socinski</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Current Opinion in Oncology</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-volisspag>
<voliss issue="2" volume="18"/>
<pagerange first="162" last="172"/>
</ref-volisspag>
<ref-text>DOI 10.1097/01.cco.0000208790.45312.25, PII 0000162220060300000011</ref-text>
</ref-info>
<ref-fulltext>Lee CB, Morris DE, Fried DB, Socinski MA. Current and evolving treatment options for limited stage small cell lung cancer. Curr Opin Oncol 2006; 18: 162-72. (Pubitemid 43740437)</ref-fulltext>
</reference>
<reference id="8">
<ref-info>
<ref-title>
<ref-titletext>Role of radiotherapy in melanoma management</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">77950118291</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Strojan P.</ce:indexed-name>
<ce:surname>Strojan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Radiol Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="44"/>
<pagerange first="1" last="12"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Strojan P. Role of radiotherapy in melanoma management. Radiol Oncol 2010; 44: 1-12.</ref-fulltext>
</reference>
<reference id="9">
<ref-info>
<ref-title>
<ref-titletext>Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: An update</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">84862832994</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>H.S.</ce:initials>
<ce:indexed-name>Park H.S.</ce:indexed-name>
<ce:surname>Park</ce:surname>
</author>
<author seq="2">
<ce:initials>V.L.</ce:initials>
<ce:indexed-name>Chiang V.L.</ce:indexed-name>
<ce:surname>Chiang</ce:surname>
</author>
<author seq="3">
<ce:initials>J.P.</ce:initials>
<ce:indexed-name>Knisely J.P.</ce:indexed-name>
<ce:surname>Knisely</ce:surname>
</author>
<author seq="4">
<ce:initials>A.C.</ce:initials>
<ce:indexed-name>Raldow A.C.</ce:indexed-name>
<ce:surname>Raldow</ce:surname>
</author>
<author seq="5">
<ce:initials>J.B.</ce:initials>
<ce:indexed-name>Yu J.B.</ce:indexed-name>
<ce:surname>Yu</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Expert Rev Anticancer Ther</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-volisspag>
<voliss volume="11"/>
<pagerange first="1731" last="1738"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Park HS, Chiang VL, Knisely JP, Raldow AC, Yu JB. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: an update. Expert Rev Anticancer Ther 2011; 11: 1731-8.</ref-fulltext>
</reference>
<reference id="10">
<ref-info>
<ref-title>
<ref-titletext>Target and peripheral dose from radiation sector motions accompanying couch repositioning of patient coordinates with the Gamma Knife® Perfexion™</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">79958104608</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:indexed-name>Tran T.A.</ce:indexed-name>
<ce:surname>Tran</ce:surname>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:indexed-name>Wu V.</ce:indexed-name>
<ce:surname>Wu</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:indexed-name>Malhotra H.</ce:indexed-name>
<ce:surname>Malhotra</ce:surname>
</author>
<author seq="4">
<ce:initials>J.P.</ce:initials>
<ce:indexed-name>Steinman J.P.</ce:indexed-name>
<ce:surname>Steinman</ce:surname>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:indexed-name>Prasad D.</ce:indexed-name>
<ce:surname>Prasad</ce:surname>
</author>
<author seq="6">
<ce:initials>M.B.</ce:initials>
<ce:indexed-name>Podgorsak M.B.</ce:indexed-name>
<ce:surname>Podgorsak</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Radiol Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-volisspag>
<voliss volume="45"/>
<pagerange first="132" last="142"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Tran TA, Wu V, Malhotra H, Steinman JP, Prasad D, Podgorsak MB. Target and peripheral dose from radiation sector motions accompanying couch repositioning of patient coordinates with the Gamma Knife® Perfexion™. Radiol Oncol 2011; 45: 132-142.</ref-fulltext>
</reference>
<reference id="11">
<ref-info>
<ref-title>
<ref-titletext>Favorable prognosis of brain metastases in small cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">0023105662</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Giannone L.</ce:indexed-name>
<ce:surname>Giannone</ce:surname>
</author>
<author seq="2">
<ce:initials>D.H.</ce:initials>
<ce:indexed-name>Johnson D.H.</ce:indexed-name>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="3">
<ce:initials>K.R.</ce:initials>
<ce:indexed-name>Hande K.R.</ce:indexed-name>
<ce:surname>Hande</ce:surname>
</author>
<author seq="4">
<ce:initials>F.A.</ce:initials>
<ce:indexed-name>Greco F.A.</ce:indexed-name>
<ce:surname>Greco</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Annals of Internal Medicine</ref-sourcetitle>
<ref-publicationyear first="1987"/>
<ref-volisspag>
<voliss issue="3" volume="106"/>
<pagerange first="386" last="389"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Giannone L, Johnson DH, Hande KR, Greco FA. Favorable prognosis of brain metastases in small cell lung cancer. Ann Intern Med 1987; 106: 386-9. (Pubitemid 17029490)</ref-fulltext>
</reference>
<reference id="12">
<ref-info>
<ref-title>
<ref-titletext>The effect of CNS metastases on the survival of patients with small cell cancer of the lung</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">0020695763</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>G.A.</ce:initials>
<ce:indexed-name>Van Hazel G.A.</ce:indexed-name>
<ce:surname>Van Hazel</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Scott M.</ce:indexed-name>
<ce:surname>Scott</ce:surname>
</author>
<author seq="3">
<ce:initials>R.T.</ce:initials>
<ce:indexed-name>Eagan R.T.</ce:indexed-name>
<ce:surname>Eagan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="1983"/>
<ref-volisspag>
<voliss issue="5" volume="51"/>
<pagerange first="933" last="937"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>van Hazel GA, Scott M, Eagan RT. The effect of CNS metastases on the survival of patients with small cell cancer of the lung. Cancer 1983; 51: 933-7. (Pubitemid 13143173)</ref-fulltext>
</reference>
<reference id="13">
<ref-info>
<ref-title>
<ref-titletext>Neurologic disorders in 203 consecutive patients with small cell lung cancer: Results of a longitudinal study</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">0029981538</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>A.G.M.</ce:initials>
<ce:indexed-name>Van Oosterhout A.G.M.</ce:indexed-name>
<ce:surname>Van Oosterhout</ce:surname>
</author>
<author seq="2">
<ce:initials>P.M.</ce:initials>
<ce:indexed-name>Van De P.M.</ce:indexed-name>
<ce:surname>Van De</ce:surname>
</author>
<author seq="3">
<ce:initials>V.G.P.M.</ce:initials>
<ce:indexed-name>Ten V.G.P.M.</ce:indexed-name>
<ce:surname>Ten</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Twijnstra A.</ce:indexed-name>
<ce:surname>Twijnstra</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<ref-volisspag>
<voliss issue="8" volume="77"/>
<pagerange first="1434" last="1441"/>
</ref-volisspag>
<ref-text>DOI 10.1002/(SICI)1097-0142(19960415)77:8&lt;1434::AID-CNCR3&gt;3.0.CO;2- C</ref-text>
</ref-info>
<ref-fulltext>van Oosterhout AG, van de Pol M, ten Velde GP, Twijnstra A. Neurologic disorder in 203 consecutive patients with small cell lung cancer. Cancer 1996; 77: 1434-41. (Pubitemid 26105377)</ref-fulltext>
</reference>
<reference id="14">
<ref-info>
<ref-title>
<ref-titletext>Lung cancer seeding along needle track after CT guided transthoracic fine-needle aspiration biopsy - Case report</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">79951890414</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:indexed-name>Pozek I.</ce:indexed-name>
<ce:surname>Pozek</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Rozman A.</ce:indexed-name>
<ce:surname>Rozman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Zdrav Vestn</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="79"/>
<pagerange first="659" last="662"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Pozek I, Rozman A. Lung cancer seeding along needle track after CT guided transthoracic fine-needle aspiration biopsy - case report. Zdrav Vestn 2010; 79: 659-62.</ref-fulltext>
</reference>
<reference id="15">
<ref-info>
<ref-title>
<ref-titletext>A comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">0021224829</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:indexed-name>Crane J.M.</ce:indexed-name>
<ce:surname>Crane</ce:surname>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:indexed-name>Nelson M.J.</ce:indexed-name>
<ce:surname>Nelson</ce:surname>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:indexed-name>Ihde D.C.</ce:indexed-name>
<ce:surname>Ihde</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Journal of Clinical Oncology</ref-sourcetitle>
<ref-publicationyear first="1984"/>
<ref-volisspag>
<voliss issue="9" volume="2"/>
<pagerange first="1017" last="1024"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Crane JM, Nelson MJ, Ihde DC, Makuch RW, Glatstein E, Zabell A, et al. A comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer. J Clin Oncol 1984; 2: 1017-24. (Pubitemid 14026259)</ref-fulltext>
</reference>
<reference id="16">
<ref-info>
<ref-title>
<ref-titletext>Prognostic factors in patients with small cell lung carcinoma</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">77956899410</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Arinc S.</ce:indexed-name>
<ce:surname>Arinc</ce:surname>
</author>
<author seq="2">
<ce:initials>U.</ce:initials>
<ce:indexed-name>Gonlugur U.</ce:indexed-name>
<ce:surname>Gonlugur</ce:surname>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:indexed-name>Devran O.</ce:indexed-name>
<ce:surname>Devran</ce:surname>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:indexed-name>Erdal N.</ce:indexed-name>
<ce:surname>Erdal</ce:surname>
</author>
<author seq="5">
<ce:initials>F.</ce:initials>
<ce:indexed-name>Ece F.</ce:indexed-name>
<ce:surname>Ece</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Ertugrul M.</ce:indexed-name>
<ce:surname>Ertugrul</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Med Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="27"/>
<pagerange first="237" last="241"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Arinc S, Gonlugur U, Devran O, Erdal N, Ece F, Ertugrul M, et al. Prognostic factors in patients with small cell lung carcinoma. Med Oncol 2010; 27: 237-41.</ref-fulltext>
</reference>
<reference id="17">
<ref-info>
<ref-title>
<ref-titletext>Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">0019419223</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>D.C.</ce:initials>
<ce:indexed-name>Ihde D.C.</ce:indexed-name>
<ce:surname>Ihde</ce:surname>
</author>
<author seq="2">
<ce:initials>R.W.</ce:initials>
<ce:indexed-name>Makuch R.W.</ce:indexed-name>
<ce:surname>Makuch</ce:surname>
</author>
<author seq="3">
<ce:initials>D.N.</ce:initials>
<ce:indexed-name>Carney D.N.</ce:indexed-name>
<ce:surname>Carney</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>American Review of Respiratory Disease</ref-sourcetitle>
<ref-publicationyear first="1981"/>
<ref-volisspag>
<voliss issue="5" volume="123"/>
<pagerange first="500" last="507"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Ihde DC, Makuch RW, Carney DN, Bunn PA, Cohen MH, Matthews MJ, et al. Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am Rev Respir Dis 1981; 123: 500-7. (Pubitemid 11098386)</ref-fulltext>
</reference>
<reference id="18">
<ref-info>
<ref-title>
<ref-titletext>The value of prognostic factors in small cell lung cancer: Results from a randomised multicenter study with minimum 5 year follow-up</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">0037374009</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>R.M.</ce:initials>
<ce:indexed-name>Bremnes R.M.</ce:indexed-name>
<ce:surname>Bremnes</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Sundstrom S.</ce:indexed-name>
<ce:surname>Sundstrom</ce:surname>
</author>
<author seq="3">
<ce:initials>U.</ce:initials>
<ce:indexed-name>Aasebo U.</ce:indexed-name>
<ce:surname>Aasebo</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Kaasa S.</ce:indexed-name>
<ce:surname>Kaasa</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Hatlevoll R.</ce:indexed-name>
<ce:surname>Hatlevoll</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Aamdal S.</ce:indexed-name>
<ce:surname>Aamdal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<ref-volisspag>
<voliss issue="3" volume="39"/>
<pagerange first="303" last="313"/>
</ref-volisspag>
<ref-text>DOI 10.1016/S0169-5002(02)00508-1, PII S0169500202005081</ref-text>
</ref-info>
<ref-fulltext>Bremnes RM, Sundstrom S, Aasebø U, Kaasa S, Hatlevoll R, Aamdal S; Norweigian Lung Cancer Study Group. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 2003; 39: 303-13. (Pubitemid 36279450)</ref-fulltext>
</reference>
<reference id="19">
<ref-info>
<ref-title>
<ref-titletext>Prophylactic cranial irradiation in patients with small-cell lung cancer: The experience at the Institute of Oncology Ljubljana</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">77958167028</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:indexed-name>Stanic K.</ce:indexed-name>
<ce:surname>Stanic</ce:surname>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:indexed-name>Kovac V.</ce:indexed-name>
<ce:surname>Kovac</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Radiol Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="44"/>
<pagerange first="180" last="186"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Stanic K, Kovac V. Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana. Radiol Oncol 2010, 44: 180-6.</ref-fulltext>
</reference>
<reference id="20">
<ref-info>
<ref-title>
<ref-titletext>Survival of patients with extensive small-cell lung cancer who have only brain metastases at initial diagnosis</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">0030978284</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Kochhar R.</ce:indexed-name>
<ce:surname>Kochhar</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Frytak S.</ce:indexed-name>
<ce:surname>Frytak</ce:surname>
</author>
<author seq="3">
<ce:initials>E.G.</ce:initials>
<ce:indexed-name>Shaw E.G.</ce:indexed-name>
<ce:surname>Shaw</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>American Journal of Clinical Oncology: Cancer Clinical Trials</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<ref-volisspag>
<voliss issue="2" volume="20"/>
<pagerange first="125" last="127"/>
</ref-volisspag>
<ref-text>DOI 10.1097/00000421-199704000-00003</ref-text>
</ref-info>
<ref-fulltext>Kochhar R, Frytak S, Shaw EG. Survival of patients with extensive small-cell lung cancer who have only brain metastases at initial diagnosis. Am J Clin Oncol 1997; 20: 125-7. (Pubitemid 27152761)</ref-fulltext>
</reference>
<reference id="21">
<ref-info>
<ref-title>
<ref-titletext>Prophylactic cranial irradiation in extensive small-cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">34547937885</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:indexed-name>Slotman B.</ce:indexed-name>
<ce:surname>Slotman</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Faivre-Finn C.</ce:indexed-name>
<ce:surname>Faivre-Finn</ce:surname>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:indexed-name>Kramer G.</ce:indexed-name>
<ce:surname>Kramer</ce:surname>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Rankin E.</ce:indexed-name>
<ce:surname>Rankin</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Snee M.</ce:indexed-name>
<ce:surname>Snee</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Hatton M.</ce:indexed-name>
<ce:surname>Hatton</ce:surname>
</author>
<author seq="7">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Postmus P.</ce:indexed-name>
<ce:surname>Postmus</ce:surname>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Collette L.</ce:indexed-name>
<ce:surname>Collette</ce:surname>
</author>
<author seq="9">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Musat E.</ce:indexed-name>
<ce:surname>Musat</ce:surname>
</author>
<author seq="10">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Senan S.</ce:indexed-name>
<ce:surname>Senan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>New England Journal of Medicine</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-volisspag>
<voliss issue="7" volume="357"/>
<pagerange first="664" last="672"/>
</ref-volisspag>
<ref-website>
<ce:e-address type="email">http://content.nejm.org/cgi/reprint/357/7/664.pdf</ce:e-address>
</ref-website>
<ref-text>DOI 10.1056/NEJMoa071780</ref-text>
</ref-info>
<ref-fulltext>Rankin E, Snee M, Hatton M, Postmus P, Collette L, Musat E; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357: 664-72. (Pubitemid 47267236)</ref-fulltext>
</reference>
<reference id="22">
<ref-info>
<ref-title>
<ref-titletext>Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">33747054805</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:indexed-name>Lee J.J.</ce:indexed-name>
<ce:surname>Lee</ce:surname>
</author>
<author seq="2">
<ce:initials>B.N.</ce:initials>
<ce:indexed-name>Bekele B.N.</ce:indexed-name>
<ce:surname>Bekele</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:indexed-name>Zhou X.</ce:indexed-name>
<ce:surname>Zhou</ce:surname>
</author>
<author seq="4">
<ce:initials>S.B.</ce:initials>
<ce:indexed-name>Cantor S.B.</ce:indexed-name>
<ce:surname>Cantor</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Komaki R.</ce:indexed-name>
<ce:surname>Komaki</ce:surname>
</author>
<author seq="6">
<ce:initials>S.L.</ce:initials>
<ce:indexed-name>Jin S.L.</ce:indexed-name>
<ce:surname>Jin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Journal of Clinical Oncology</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-volisspag>
<voliss issue="22" volume="24"/>
<pagerange first="3597" last="3603"/>
</ref-volisspag>
<ref-text>DOI 10.1200/JCO.2006.06.0632</ref-text>
</ref-info>
<ref-fulltext>Lee JJ, Bekele BN, Zhou X, Cantor SB, Komaki R, Lee JS. Decision analysis for prophylactic cranial irradiation for patients with small sell lung cancer. J Clin Oncol 2006; 24: 3597-603. (Pubitemid 46630532)</ref-fulltext>
</reference>
<reference id="23">
<ref-info>
<ref-title>
<ref-titletext>Prophylactic cranial irradiation in lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">76749156703</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Blanchard P.</ce:indexed-name>
<ce:surname>Blanchard</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Le Pechoux C.</ce:indexed-name>
<ce:surname>Le Pechoux</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr Opin Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="22"/>
<pagerange first="94" last="101"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Blanchard P, Le Pechoux C. Prophylactic cranial irradiation in lung cancer. Curr Opin Oncol 2010; 22: 94-101.</ref-fulltext>
</reference>
<reference id="24">
<ref-info>
<ref-title>
<ref-titletext>Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">0345062339</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Auperin A.</ce:indexed-name>
<ce:surname>Aupérin</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Arriagada R.</ce:indexed-name>
<ce:surname>Arriagada</ce:surname>
</author>
<author seq="3">
<ce:initials>J.P.</ce:initials>
<ce:indexed-name>Pignon J.P.</ce:indexed-name>
<ce:surname>Pignon</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Le Pechoux C.</ce:indexed-name>
<ce:surname>Le Péchoux</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Gregor A.</ce:indexed-name>
<ce:surname>Gregor</ce:surname>
</author>
<author seq="6">
<ce:initials>R.J.</ce:initials>
<ce:indexed-name>Stephens R.J.</ce:indexed-name>
<ce:surname>Stephens</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<ref-volisspag>
<voliss volume="341"/>
<pagerange first="476" last="478"/>
</ref-volisspag>
<ref-text>Prophylactic Cranial Irradiation Overview Collaborative Group</ref-text>
</ref-info>
<ref-fulltext>Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341: 476-8.</ref-fulltext>
</reference>
<reference id="25">
<ref-info>
<ref-title>
<ref-titletext>Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): A randomised clinical trial</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">65449145578</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Le Pechoux C.</ce:indexed-name>
<ce:surname>Le Pechoux</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Dunant A.</ce:indexed-name>
<ce:surname>Dunant</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Senan S.</ce:indexed-name>
<ce:surname>Senan</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Wolfson A.</ce:indexed-name>
<ce:surname>Wolfson</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Quoix E.</ce:indexed-name>
<ce:surname>Quoix</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Faivre-Finn C.</ce:indexed-name>
<ce:surname>Faivre-Finn</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss volume="10"/>
<pagerange first="467" last="474"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Le Pechoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009; 10: 467-74.</ref-fulltext>
</reference>
<reference id="26">
<ref-info>
<ref-title>
<ref-titletext>Prophylactic cranial irradiation in small cell lung cancer: A systematic review of the literature with meta-analysis</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">3042759877</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>A.P.</ce:initials>
<ce:indexed-name>Meert A.P.</ce:indexed-name>
<ce:surname>Meert</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Paesmans M.</ce:indexed-name>
<ce:surname>Paesmans</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Berghmans T.</ce:indexed-name>
<ce:surname>Berghmans</ce:surname>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:indexed-name>Martin B.</ce:indexed-name>
<ce:surname>Martin</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Mascaux C.</ce:indexed-name>
<ce:surname>Mascaux</ce:surname>
</author>
<author seq="6">
<ce:initials>F.</ce:initials>
<ce:indexed-name>Vallot F.</ce:indexed-name>
<ce:surname>Vallot</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<ref-volisspag>
<voliss volume="1"/>
<pagerange first="5"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Meert AP, Paesmans M, Berghmans T, Martin B, Mascaux C, Vallot F, et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer 2001; 1: 5.</ref-fulltext>
</reference>
<reference id="27">
<ref-info>
<ref-title>
<ref-titletext>Prophylactic cranial irradiation in lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">79953090908</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Paumier A.</ce:indexed-name>
<ce:surname>Paumier</ce:surname>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:indexed-name>Cuenca X.</ce:indexed-name>
<ce:surname>Cuenca</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Le Pechoux C.</ce:indexed-name>
<ce:surname>Le Péchoux</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Treat Rev</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-volisspag>
<voliss volume="37"/>
<pagerange first="261" last="265"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Paumier A, Cuenca X, Le Péchoux C. Prophylactic cranial irradiation in lung cancer. Cancer Treat Rev 2011; 37: 261-5.</ref-fulltext>
</reference>
<reference id="28">
<ref-info>
<ref-title>
<ref-titletext>Current status of second-line treatment and novel therapies for small cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">34548420569</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Tiseo M.</ce:indexed-name>
<ce:surname>Tiseo</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Ardizzoni A.</ce:indexed-name>
<ce:surname>Ardizzoni</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Journal of Thoracic Oncology</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-volisspag>
<voliss issue="8" volume="2"/>
<pagerange first="764" last="772"/>
</ref-volisspag>
<ref-text>DOI 10.1097/JTO.0b013e3180986262, PII 0124389420070800000017</ref-text>
</ref-info>
<ref-fulltext>Tiseo M, Ardizzoni A. Current status of second-line treatment and novel therapies for small cell lung cancer. J Thorac Oncol 2007; 2: 764-72. (Pubitemid 47357534)</ref-fulltext>
</reference>
<reference id="29">
<ref-info>
<ref-title>
<ref-titletext>Advances in the treatment of small-cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">79954574461</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>G.P.</ce:initials>
<ce:indexed-name>Kalemkerian G.P.</ce:indexed-name>
<ce:surname>Kalemkerian</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Semin Respir Crit Care Med</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-volisspag>
<voliss volume="32"/>
<pagerange first="94" last="101"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Kalemkerian GP. Advances in the treatment of small-cell lung cancer. Semin Respir Crit Care Med 2011; 32: 94-101.</ref-fulltext>
</reference>
<reference id="30">
<ref-info>
<ref-title>
<ref-titletext>Emerging drugs for small-cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">71649095728</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:indexed-name>Metro G.</ce:indexed-name>
<ce:surname>Metro</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:indexed-name>Cappuzzo F.</ce:indexed-name>
<ce:surname>Cappuzzo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Expert Opin Emerg Drugs</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss volume="14"/>
<pagerange first="591" last="606"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Metro G, Cappuzzo F. Emerging drugs for small-cell lung cancer. Expert Opin Emerg Drugs 2009; 14: 591-606.</ref-fulltext>
</reference>
</bibliography></tail></bibrecord></item></abstracts-retrieval-response>